Lexaria Bioscience begins dosing in comprehensive GLP-1 animal study

Lexaria Bioscience announces that dosing has begun in the 12-week animal study WEIGHT-A24-1 to model diabetes treatment and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 drugs and DehydraTECH-processed cannabidiol, alone and in combination in diabetic preconditioned rats. Each arm of the Study will be dosed for a 12-week period following an acclimation period. During the Study, over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for purposes of detailed pharmacokinetic drug delivery analyses. Body weight and blood glucose readings will be taken prior to Study start and at regular intervals during and at conclusion of the dosing period. Upon completion of the Study, brain tissue will be analysed to help determine whether DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms, as Lexaria has evidenced numerous times in previous similar animal studies. The Study will also include a comprehensive battery of liver and kidney function testing and blood chemistry analyses.